Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Given that 5-HT3 receptors are indirect inhibitors of cortico-mesolimbic DA release, the
5-HT3 receptor antagonist ondansetron augmentation might potentially have efficacy in the
treatment of resistant Obsessive Comulsive Disorder (OCD) patients on combined SRIs and
antipsychotics.